We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tyratech (DI/S) | LSE:TYR | London | Ordinary Share | COM SHS USD0.001 (DI / REGS) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.95 | 2.70 | 3.20 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMTYR TIDMTYRU
RNS Number : 3546I
TyraTech, Inc.
25 March 2015
TyraTech, Inc.
("TyraTech" or the "Company")
Vamousse(R) head lice treatment now distributed by CVS in the USA
TyraTech, Inc. (AIM: TYR and TYRU), a life sciences company focused on nature-derived insect and parasite control products, is pleased to announce that it has secured listings for its Vamousse Treatment product with the CVS Pharmacy Group in the USA.
CVS Pharmacy
CVS Pharmacy is the second largest pharmacy chain after Walgreens in the United States, with more than 7,600 stores and 100 million American customers each year. This listing, which follows the recent announcement of deals with the top three pharmaceutical distributors in the USA, represents a further key milestone for the roll-out of TyraTech's Vamousse products in America. It is expected that the Treatment product will be available in the majority of CVS stores nationwide in the USA from the end of April 2015.
Tesco update
In addition to the progress in the USA, we are pleased to announce positive developments in our UK distribution network also. Tesco, which had until recently been selling the Vamousse Treatment product through its pharmacy counters, will also place the product into open shelving, making it more accessible and visible to customers. Tesco has also confirmed separately, that it will almost double the number of stores stocking TyraTech's Vamousse Treatment product.
Bruno Jactel, Chief Executive Officer, said: "The CVS listing is probably our most important milestone this year as it firmly establishes our product in the pharmacy segment in the USA and significantly enhances the profile of our brand. I would like to thank our partner, the Greenwood Group, which has been instrumental in establishing the commercial relationship with CVS and our retail partners in the USA. Together with the recent announcement of the three biggest pharmaceutical distributors in the USA, and Lloyds and Day Lewis in the UK, we are very excited by the growth opportunities presented by the continually expanding distribution network for Vamousse products."
Further information on Vamousse(R) is available on the Company's website at http://www.vamousselice.com/
TyraTech Inc. Bruno Jactel, Chief Executive Tel: +1 919 Officer 415 4340 Vince Morgus, Chief Financial Tel: +1 919 Officer & Treasurer 415 4287 SPARK Advisory Partners Limited, Tel: +44203 Nominated Adviser 368 3552 Matt Davis / Mark Brady Tel: +44203 368 3551 Allenby Capital Limited , Joint Broker Tel: +44 20 Chris Crawford 3328 5656 Whitman Howard Limited, Joint Broker Tel: +44 20 Ranald Mc-Gregor Smith / 7659 1240 Niall Devins Walbrook, Financial PR and IR Tel: +44 20 Nick Rome /Guy McDougall 7933 8790
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBLGDXSSDBGUS
1 Year Tyratech Chart |
1 Month Tyratech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions